CSIMarket Company Name, Ticker, Competitors, else..
 
Evoke Pharma Inc   (NASDAQ: EVOK)
Other Ticker:  
 
 
Price: $4.1000 $0.02 0.490%
Day's High: $4.225 Week Perf: -2.84 %
Day's Low: $ 4.03 30 Day Perf: -28.32 %
Volume (M): 13 52 Wk High: $ 15.13
Volume (M$): $ 52 52 Wk Avg: $6.64
Open: $4.20 52 Wk Low: $3.54



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Evoke Pharma Inc
Evoke Pharma Inc is a specialty pharmaceutical company that focuses on developing and commercializing therapeutic solutions for gastrointestinal diseases. The company's lead product is Gimoti, a nasal spray used for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Evoke Pharma aims to provide innovative and convenient treatment options for patients suffering from these conditions.


   Company Address: 420 Stevens Avenue Solana Beach 92075 CA
   Company Phone Number: 345-1494   Stock Exchange / Ticker: NASDAQ EVOK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD        7.96% 
AMRX   -6.14%    
BHC   -6.65%    
MNK   -39.2%    
TEVA   -0.43%    
VTRS   -1.09%    
• View Complete Report
   



Stock Market Announcement

Evoke Pharma Initiates 1-for-12 Reverse Stock Split to Enhance Shareholder Value

Published Tue, Jul 30 2024 12:31 PM UTC


Date: August 1, 2024
SOLANA BEACH, Calif. - Evoke Pharma, Inc. (NASDAQ: EVOK), a pioneering specialty pharmaceutical company, announced today that its board of directors has approved a 1-for-12 reverse stock split of the company s common stock. This strategic move aims to enhance shareholder value and solidify Evoke Pharma s position in the market focused primarily ...
Management Announcement

Evoke Pharma: Seizing Opportunities to Revolutionize GI Therapeutics with Recent Underwritten Public Offering

Published Fri, Feb 9 2024 12:31 PM UTC


Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company specializing in gastrointestinal (GI) disease treatments, has recently disclosed the pricing details of its underwritten public offering. The company aims to raise gross proceeds of up to $30 million through this o...
Evoke Pharma Inc

Evoke Pharma Inc.'s Revenue Soars, Marking a Significant Step Towards Profitability in Q3 2023

Evoke Pharma Inc, a pharmaceutical company specializing in the development of novel treatments for gastrointestinal diseases, reported a decent revenue improvement in its July to September 30, 2023, financial period. The company's revenue increased by a significant 87.821% to $1.56 million compared to the same period in the previous year. This improvement in revenue also supported a reduction in losses, with earnings per share improving from $-0.60 to $-0.51.
Comparing the third quarter of 2023 to the previous quarter, Evoke Pharma Inc saw a 38.139% increase in revenue from $1.13 million, and the company's income per share also improved from $-0.56 per share. These positive results indicate that the company is making progress and moving towards profitability.
Evoke Pharma Inc

EVOK's Phenomenal Performance Shines Through in Recent Fiscal Period

The stock market has been witnessing some exhilarating developments lately, and one company that has been particularly catching the eye of investors is Evoke Pharma Inc. With the most recent fiscal period showcasing some impressive figures, it's no wonder that market enthusiasts have been buzzing with anticipation.
To start with, Evoke Pharma Inc demonstrated remarkable improvement in its earnings per share (EPS) performance. In comparison to a loss of $0.71 per share a year ago, the company managed to decrease its loss to just $0.56 per share. This positive change is truly noteworthy, showing a clear commitment to enhancing profitability and shareholder value.
Evoke Pharma Inc

Evoke Pharma Inc Shines with Phenomenal 93.701% Revenue Surge in Q1 2023 Earnings, Despite Some Setbacks

Investors in Evoke Pharma Inc ought to take into account the latest report released by the company, which highlights both positive and negative developments in the first quarter of 2023. While the company experienced a surge in shortfall per share, this increase was offset by strong growth in revenue, with a substantial year-on-year increase of 93.701%. Sequentially, the revenue also surged, albeit to a lesser extent, by 1.763%.
It must be noted, however, that Evoke Pharma Inc also realized a larger net shortfall of $-2.243 million in the first quarter of 2023, compared to $-2.174 million a year ago. This highlights the importance of keeping an eye on the company's financial earnings, with the next report expected to be released on August 09, 2023.
Despite this negative development, Evoke Pharma Inc remains an attractive investment option given the significant increase in revenue. Investors would do well to analyze this data closely and to adjust their investment strategies accordingly. Moreover, the company has maintained its financial footing throughout the pandemic and has continued to deliver strong financial results even in these challenging times.






Evoke Pharma Inc's Segments

  Evoke Pharma Inc Outlook

On May 14 2024 the Evoke Pharma Inc provided following guidance

Evoke Pharma Inc. has released its first quarter financial results for 2024, showing a significant 114% year-over-year ...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com